Financhill
Sell
30

CRNX Quote, Financials, Valuation and Earnings

Last price:
$53.87
Seasonality move :
-9.59%
Day range:
$53.15 - $54.78
52-week range:
$33.67 - $62.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.01x
Volume:
150.3K
Avg. volume:
739K
1-year change:
50.21%
Market cap:
$5B
Revenue:
$4M
EPS (TTM):
-$3.73

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CRNX
Crinetics Pharmaceuticals
$239.9K -$0.91 -30.67% -1.95% $75.07
BMEA
Biomea Fusion
-- -$0.91 -- -4.38% $40.56
CLSD
Clearside Biomedical
$122.9K -$0.12 -95.36% -35% --
IBIO
iBio
-- -$0.46 -100% -89.82% --
NBY
NovaBay Pharmaceuticals
$2.6M -$0.31 -60.77% -99.16% --
PTN
Palatin Technologies
-- -$0.51 -100% -25% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CRNX
Crinetics Pharmaceuticals
$53.94 $75.07 $5B -- $0.00 0% --
BMEA
Biomea Fusion
$4.01 $40.56 $145.3M -- $0.00 0% --
CLSD
Clearside Biomedical
$0.93 -- $70.5M -- $0.00 0% 8.49x
IBIO
iBio
$2.42 -- $22.1M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.54 -- $2.6M -- $0.00 0% 0.06x
PTN
Palatin Technologies
$0.99 -- $19.4M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CRNX
Crinetics Pharmaceuticals
-- 0.746 -- 15.96x
BMEA
Biomea Fusion
-- -0.311 -- --
CLSD
Clearside Biomedical
-- 3.239 -- 4.36x
IBIO
iBio
4.41% 6.097 5.41% 3.89x
NBY
NovaBay Pharmaceuticals
4.54% 0.704 1.51% 0.75x
PTN
Palatin Technologies
-- -0.872 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CRNX
Crinetics Pharmaceuticals
-- -$87.8M -42.43% -42.43% -20747.62% -$63.4M
BMEA
Biomea Fusion
-- -$34M -- -- -- -$25.4M
CLSD
Clearside Biomedical
$1M -$5.9M -- -- -503.95% -$6M
IBIO
iBio
-- -$4.1M -90.99% -148.3% -1820.57% -$3.7M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M

Crinetics Pharmaceuticals vs. Competitors

  • Which has Higher Returns CRNX or BMEA?

    Biomea Fusion has a net margin of -18560.15% compared to Crinetics Pharmaceuticals's net margin of --. Crinetics Pharmaceuticals's return on equity of -42.43% beat Biomea Fusion's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CRNX
    Crinetics Pharmaceuticals
    -- -$0.96 $830.8M
    BMEA
    Biomea Fusion
    -- -$0.91 --
  • What do Analysts Say About CRNX or BMEA?

    Crinetics Pharmaceuticals has a consensus price target of $75.07, signalling upside risk potential of 39.18%. On the other hand Biomea Fusion has an analysts' consensus of $40.56 which suggests that it could grow by 911.36%. Given that Biomea Fusion has higher upside potential than Crinetics Pharmaceuticals, analysts believe Biomea Fusion is more attractive than Crinetics Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRNX
    Crinetics Pharmaceuticals
    8 1 0
    BMEA
    Biomea Fusion
    4 2 0
  • Is CRNX or BMEA More Risky?

    Crinetics Pharmaceuticals has a beta of 0.597, which suggesting that the stock is 40.297% less volatile than S&P 500. In comparison Biomea Fusion has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CRNX or BMEA?

    Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomea Fusion offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. Biomea Fusion pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRNX or BMEA?

    Crinetics Pharmaceuticals quarterly revenues are $399K, which are larger than Biomea Fusion quarterly revenues of --. Crinetics Pharmaceuticals's net income of -$76.8M is lower than Biomea Fusion's net income of -$32.8M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while Biomea Fusion's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus -- for Biomea Fusion. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRNX
    Crinetics Pharmaceuticals
    -- -- $399K -$76.8M
    BMEA
    Biomea Fusion
    -- -- -- -$32.8M
  • Which has Higher Returns CRNX or CLSD?

    Clearside Biomedical has a net margin of -18560.15% compared to Crinetics Pharmaceuticals's net margin of -740.66%. Crinetics Pharmaceuticals's return on equity of -42.43% beat Clearside Biomedical's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CRNX
    Crinetics Pharmaceuticals
    -- -$0.96 $830.8M
    CLSD
    Clearside Biomedical
    -- -$0.10 -$34.8M
  • What do Analysts Say About CRNX or CLSD?

    Crinetics Pharmaceuticals has a consensus price target of $75.07, signalling upside risk potential of 39.18%. On the other hand Clearside Biomedical has an analysts' consensus of -- which suggests that it could grow by 545.86%. Given that Clearside Biomedical has higher upside potential than Crinetics Pharmaceuticals, analysts believe Clearside Biomedical is more attractive than Crinetics Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRNX
    Crinetics Pharmaceuticals
    8 1 0
    CLSD
    Clearside Biomedical
    0 0 0
  • Is CRNX or CLSD More Risky?

    Crinetics Pharmaceuticals has a beta of 0.597, which suggesting that the stock is 40.297% less volatile than S&P 500. In comparison Clearside Biomedical has a beta of 2.292, suggesting its more volatile than the S&P 500 by 129.225%.

  • Which is a Better Dividend Stock CRNX or CLSD?

    Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clearside Biomedical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. Clearside Biomedical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRNX or CLSD?

    Crinetics Pharmaceuticals quarterly revenues are $399K, which are smaller than Clearside Biomedical quarterly revenues of $1M. Crinetics Pharmaceuticals's net income of -$76.8M is lower than Clearside Biomedical's net income of -$7.7M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while Clearside Biomedical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus 8.49x for Clearside Biomedical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRNX
    Crinetics Pharmaceuticals
    -- -- $399K -$76.8M
    CLSD
    Clearside Biomedical
    8.49x -- $1M -$7.7M
  • Which has Higher Returns CRNX or IBIO?

    iBio has a net margin of -18560.15% compared to Crinetics Pharmaceuticals's net margin of -4444.57%. Crinetics Pharmaceuticals's return on equity of -42.43% beat iBio's return on equity of -148.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRNX
    Crinetics Pharmaceuticals
    -- -$0.96 $830.8M
    IBIO
    iBio
    -- -$0.46 $22.3M
  • What do Analysts Say About CRNX or IBIO?

    Crinetics Pharmaceuticals has a consensus price target of $75.07, signalling upside risk potential of 39.18%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 49.05%. Given that iBio has higher upside potential than Crinetics Pharmaceuticals, analysts believe iBio is more attractive than Crinetics Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRNX
    Crinetics Pharmaceuticals
    8 1 0
    IBIO
    iBio
    0 0 0
  • Is CRNX or IBIO More Risky?

    Crinetics Pharmaceuticals has a beta of 0.597, which suggesting that the stock is 40.297% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

  • Which is a Better Dividend Stock CRNX or IBIO?

    Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRNX or IBIO?

    Crinetics Pharmaceuticals quarterly revenues are $399K, which are larger than iBio quarterly revenues of $175K. Crinetics Pharmaceuticals's net income of -$76.8M is lower than iBio's net income of -$4M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRNX
    Crinetics Pharmaceuticals
    -- -- $399K -$76.8M
    IBIO
    iBio
    -- -- $175K -$4M
  • Which has Higher Returns CRNX or NBY?

    NovaBay Pharmaceuticals has a net margin of -18560.15% compared to Crinetics Pharmaceuticals's net margin of -49.65%. Crinetics Pharmaceuticals's return on equity of -42.43% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRNX
    Crinetics Pharmaceuticals
    -- -$0.96 $830.8M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About CRNX or NBY?

    Crinetics Pharmaceuticals has a consensus price target of $75.07, signalling upside risk potential of 39.18%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Crinetics Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Crinetics Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRNX
    Crinetics Pharmaceuticals
    8 1 0
    NBY
    NovaBay Pharmaceuticals
    0 0 0
  • Is CRNX or NBY More Risky?

    Crinetics Pharmaceuticals has a beta of 0.597, which suggesting that the stock is 40.297% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

  • Which is a Better Dividend Stock CRNX or NBY?

    Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRNX or NBY?

    Crinetics Pharmaceuticals quarterly revenues are $399K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Crinetics Pharmaceuticals's net income of -$76.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRNX
    Crinetics Pharmaceuticals
    -- -- $399K -$76.8M
    NBY
    NovaBay Pharmaceuticals
    0.06x -- $2.4M -$1.2M
  • Which has Higher Returns CRNX or PTN?

    Palatin Technologies has a net margin of -18560.15% compared to Crinetics Pharmaceuticals's net margin of -2357.27%. Crinetics Pharmaceuticals's return on equity of -42.43% beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CRNX
    Crinetics Pharmaceuticals
    -- -$0.96 $830.8M
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
  • What do Analysts Say About CRNX or PTN?

    Crinetics Pharmaceuticals has a consensus price target of $75.07, signalling upside risk potential of 39.18%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Crinetics Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Crinetics Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRNX
    Crinetics Pharmaceuticals
    8 1 0
    PTN
    Palatin Technologies
    0 0 0
  • Is CRNX or PTN More Risky?

    Crinetics Pharmaceuticals has a beta of 0.597, which suggesting that the stock is 40.297% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

  • Which is a Better Dividend Stock CRNX or PTN?

    Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRNX or PTN?

    Crinetics Pharmaceuticals quarterly revenues are $399K, which are larger than Palatin Technologies quarterly revenues of $350K. Crinetics Pharmaceuticals's net income of -$76.8M is lower than Palatin Technologies's net income of -$7.8M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRNX
    Crinetics Pharmaceuticals
    -- -- $399K -$76.8M
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
87
PSIX alert for Dec 26

Power Solutions International [PSIX] is up 4.07% over the past day.

Buy
65
TSLL alert for Dec 26

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 2.42% over the past day.

Buy
75
SMLR alert for Dec 26

Semler Scientific [SMLR] is down 1.12% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock